Results 231 to 240 of about 54,700 (373)

Drug Eruptions

International Journal of Clinical Practice, 1968
openaire   +2 more sources

Unusual fixed drug eruption due to rifampicin

, 2000
A K Jaiswal, SS Vaishampayan, R. N. Verma, K. VARADA   +3 more
openalex   +1 more source

LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES [PDF]

, 2007
İlhami Kıkı, Mustafa Atasoy, Nesrin Gürsan, Mehmet Ali Gündoğdu, Fuat Erdem, Şevki Özdemir   +5 more
openalex   +1 more source

Inflammatory Nail Disorders in Skin of Color: A Systematic Review of Clinical and Onychoscopic Manifestations

International Journal of Dermatology, EarlyView.
ABSTRACT Despite increasing attention regarding skin diseases in individuals with skin of color (SoC), there remains a significant gap in understanding and identifying inflammatory nail disorders in this population. This systematic review aims to synthesize the clinical and onychoscopic features of inflammatory nail disorders in patients with SoC ...
Lea Tordjman, Jason Thomas, Antonella Tosti, Brian W. Morrison   +3 more
wiley   +1 more source

Fixed Drug Eruptions Due To/Caused by Levocetirizine and Cetirizine: An Uncommon Adverse Cutaneous Drug Reaction to Commonly Used Piperazine Derivatives. [PDF]

Indian Dermatol Online J
Tyagi M, Ahuja R, Patel V, Sahni K, Taneja N, Gupta S.   +5 more
europepmc   +1 more source

Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. [PDF]

J Am Acad Dermatol, 2018
Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.   +11 more
europepmc   +1 more source

Itraconazole-induced Drug Eruption Confirmed by Challenge Test

, 2000
Takeshi Goto
openalex   +1 more source

Cutaneous Side Effects of PD‐1 Inhibitors: A Single‐Center Retrospective Study

International Journal of Dermatology, EarlyView.
ABSTRACT Background The introduction of immune checkpoint inhibitors (ICIs) opened a new era in cancer immunotherapy. In particular, PD‐1 inhibitors have shown remarkable efficacy in various cancers, most notably melanoma. However, the widespread use of immune checkpoint inhibitors comes with the challenge of immune‐related adverse events (irAEs), with
Melánia Pozsgai, Udoh Frieda‐Rex Sebastian, Péter Oláh, Viktória Németh, Rolland Gyulai, Zsuzsanna Lengyel   +5 more
wiley   +1 more source

Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions

, 2000
Nikhil Yawalkar, M Shrikhande, Yvonne Hari, Helga Nievergelt, Lasse R. Braathen, Werner J. Pichler   +5 more
openalex   +1 more source

Comprehensive Literature Review Evaluating the Use, Safety, and Efficacy of Subcutaneous Methotrexate in the Treatment of Adult Patients With Moderate‐To‐Severe Plaque‐Type Psoriasis

International Journal of Dermatology, EarlyView.
ABSTRACT Methotrexate (MTX) is a conventional systemic therapy widely used to treat chronic plaque‐type psoriasis, a chronic inflammatory skin disease that significantly impacts patients' quality of life. MTX can be administered orally or subcutaneously. Over the past decades, the use of subcutaneous versus oral MTX has been a subject of ongoing debate
Manuelle Viguier, José‐Manuel Carrascosa‐Carrillo, Pariyawan Rakvit, Maria‐Magdalena Constantin, Alice‐Anaïs Varlet, Solenn Le Clanche, Linda A. W. Verhagen, Wolf‐Henning Boehncke   +7 more
wiley   +1 more source